R&D Closed and Collaborative: Mergers, acquisitions, and partner... As we head further into H2, a final look back to the summer’s industry mergers and acquisiti
R&D Closed and Collaborative: Mergers, acquisitions, and partner... Summer’s stretch having drawn out a longer return to our round-ups, as the days shorten and we firmly enter autumn, pharmaphorum takes a look back at the industry
R&D Closed and Collaborative: Mergers, acquisitions, and partner... Welcome to a new pharmaphorum round-up.
Market Access A year of major M&A ahead? The previous few years have seen a slowdown in M&A across the industry, as companies take a cautious approach to expansion.
News Chiesi expands rare disease portfolio with Amryt Pharma acqu... Biopharma and healthcare group Chiesi Farmaceutici S.p.A.
News Boost for mRNA as Moderna to acquire OriCiro for $85 million Biotech Moderna, Inc. and OriCiro Genomics K.K.
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
